A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of ESO-T01 for patients with relapsed/refractory multiple myeloma.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology